` PAR (Paradigm Biopharmaceuticals Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PAR
vs
S&P/ASX 300

Over the past 12 months, PAR has significantly outperformed S&P/ASX 300, delivering a return of 33% compared to the S&P/ASX 300's 7% growth.

Stocks Performance
PAR vs S&P/ASX 300

Loading

Performance Gap
PAR vs S&P/ASX 300

Loading
PAR
S&P/ASX 300
Difference

Performance By Year
PAR vs S&P/ASX 300

Loading
PAR
S&P/ASX 300
Add Stock

Competitors Performance
Paradigm Biopharmaceuticals Ltd vs Peers

S&P/ASX 300
PAR
ABBV
AMGN
GILD
VRTX
Add Stock

Paradigm Biopharmaceuticals Ltd
Glance View

Market Cap
126.6m AUD
Industry
Biotechnology

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.

PAR Intrinsic Value
0.16 AUD
Overvaluation 51%
Intrinsic Value
Price
Back to Top